ArticleOncology letters2026
Comparative evaluation of microRNA detection in plasma, urine and liquid-based cytology for high-grade cervical intraepithelial neoplasia.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Discovery and analytical assessment of urinary miRNA biomarkers for cervical cancer using advanced small RNA sequencing.Translational oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liquid biopsy offers a minimally invasive approach for cancer diagnosis by detecting circulating biomarkers, such as microRNAs (miRNAs), in different types of specimens. The present study aimed to identify the most effective specimen for miRNA detection in cervical cancer precursor lesions by comparing plasma, urine and liquid-based cytology (LBC). A total of 798 miRNAs were analyzed using NanoString technology in 24 women, equally divided between those with high-grade cervical intraepithelial neoplasia (2/3) and controls with negative Pap and human papillomavirus tests. Comparative analyses revealed that LBC exhibited the highest detection efficiency, with only 1.75% of miRNAs demonstrating low counts, compared with 20.68% in plasma and 15.79% in urine. Additionally, LBC exhibited 21.3% of miRNAs above the 9th decile of expression, compared with 5.89% in plasma and 2.88% in urine. LBC revealed the most consistent detection performance across samples, establishing its potential as the most effective specimen for detecting cervical cancer precursor lesions biomarkers. Plasma also showed promise as a detection medium, whilst urine exhibited higher variability and lower detection consistency. In conclusion, LBC demonstrated the highest efficacy for miRNA detection among the specimen types tested. Plasma remains a viable alternative, whilst urine presents challenges due to its inherent variability. These results underscore the importance of specimen selection for optimizing diagnostic sensitivity in cervical cancer precursor lesions screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.